 |
 |
 |
 |
 |
|
immunotherapySelected PublicationsBENDANDI M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer. 2009 Sep;9(9):675-81.
ABSTRACT COURTESY OF PUBMEDMARTINEZ-FORERO I, GARCIA-MUNOZ R, MARTINEZ-PASAMAR S, INOGES S, LOPEZ-DIAZ DE CERIO A, PALACIOS R, SEPULCRE J, MORENO B, GONZALEZ Z, FERNANDEZ-DIEZ B, MELERO I, BENDANDI M, VILLOSLADA P. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol. 2008 Feb;38(2):576-86.
ABSTRACT COURTESY OF PUBMEDREDONDO P, DEL OLMO J, LÓPEZ-DIAZ DE CERIO A, INOGES S, MARQUINA M, MELERO I, BENDANDI M. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol. 2007 Jul;127(7):1673-80. ABSTRACT COURTESY OF PUBMEDDE CERIO AL, ZABALEGUI N, RODRÍGUEZ-CALVILLO M, INOGÉS S, BENDANDI M. Anti-idiotype antibodies in cancer treatment. Oncogene. 2007 May 28;26(25):3594-602. Review. ABSTRACT COURTESY OF PUBMEDRADCLIFFE CM, ARNOLD JN, SUTER DM, WORMALD MR, HARVEY DJ, ROYLE L, MIMURA Y, KIMURA Y, SIM RB, INOGÈS S, RODRIGUEZ-CALVILLO M, ZABALEGUI N, DE CERIO AL, POTTER KN, MOCKRIDGE CI, DWEK RA, BENDANDI M, RUDD PM, STEVENSON FK. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem. 2007 Mar 9;282(10):7405-15. ABSTRACT COURTESY OF PUBMEDINOGÈS S, RODRÌGUEZ-CALVILLO M, ZABALEGUI N, LÒPEZ-DÌAZ DE CERIO A, VILLANUEVA H, SORIA E, SUÁREZ L, RODRÍGUEZ-CABALLERO A, PASTOR F, GARCÍA-MUÑÓZ R, PANIZO C, PÈREZ-CALVO J, MELERO I, ROCHA E, ORFAO A, BENDANDI M. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301. ABSTRACT COURTESY OF PUBMEDBENDANDI M, RODRÍGUEZ-CALVILLO M, INOGÉS S, LÓPEZ-DÍAZ DE CERIO A, PÉREZ-SIMÓN JA, RODRÍGUEZ-CABALLERO A, GARCÍA-MONTERO A, ALMEIDA J, ZABALEGUI N, GIRALDO P, SAN MIGUEL J, ORFAO A. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma. 2006 Jan;47(1):29-37. ABSTRACT COURTESY OF PUBMEDREDONDO P, LLORET P, IDOATE M, INOGES S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol. 2005 Sep;30(5):541-5. ABSTRACT COURTESY OF PUBMEDTIRAPU I, HUARTE E, ALFARO C, ARINA A, MURILLO O, INOGÉS SANCHO S, BENDANDI M, MAZZOLINI G, MELERO I. Critical appraisal of the current status of dendritic cell based therapy. Inmunología. 2005;24(1):23-32. MAZZOLINI G, RODRÍGUEZ-CALVILLO M, INOGÉS SANCHO S, PRIETO J, MELERO I. Desarrollo de un producto de terapia génica. Desde el laboratorio a la clínica. Medicine. 2005;9:2206-2209. RODRÍGUEZ-CALVILLO M, INOGÉS SANCHO S, MAZZOLINI G, MELERO I. Desarrollo de protocolos de inmunoterapia tumoral con células dendríticas. Medicine. 2005;9:2199-2202. INOGÉS SANCHO S, RODRÍGUEZ-CALVILLO M, MAZZOLINI G, MELERO I. Aplicaciones actuales y futuras de la inmunoterapia adoptiva con linfocitos activados. Medicine. 2005;9:2202-2206. REDONDO P, LLORET P, ANDREU EJ, INOGES S. Imatinib mesylate in cutaneous melanoma. J Invest Dermatol. 2004 Dec;123(6):1208-9. ABSTRACT COURTESY OF PUBMEDRODRÍGUEZ-CALVILLO M, INOGÉS S, LÓPEZ-DÍAZ DE CERIO A, ZABALEGUI N, VILLANUEVA H, BENDANDI M. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit Rev Oncol Hematol. 2004 Oct;52(1):1-7. Review. ABSTRACT COURTESY OF PUBMEDZABALEGUI N, DE CERIO AL, INOGÉS S, RODRÍGUEZ-CALVILLO M, PÉREZ-CALVO J, HERNÁNDEZ M, GARCÍA-FONCILLAS J, MARTÍN-ALGARRA S, ROCHA E, BENDANDI M. Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies. Haematologica. 2004 May;89(5):541-6. ABSTRACT COURTESY OF PUBMEDGONZÁLEZ I, ANDREU EJ, PANIZO A, INOGÉS S, FONTALBA A, FERNÁNDEZ-LUNA JL, GABOLI M, SIERRASESÚMAGA L, MARTÍN-ALGARRA S, PARDO J, PRÓSPER F, DE ALAVA E. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res. 2004 Jan 15;10(2):751-61. ABSTRACT COURTESY OF PUBMEDINOGÉS S, RODRÍGUEZ CALVILLO M, LÓPEZ DÍAZ DE CERIO A, ZABALEGUI N, MELERO I, SÁNCHEZ IBARROLA A, ROCHA E, BENDANDI M. Inmunoterapia activa en el tratamiento de neoplasias hematológicas. An Sist Sanit Navar. 2004 Jan-Apr;27(1):45-62. Review. ABSTRACT COURTESY OF PUBMEDINOGÉS S, RODRÍGUEZ-CALVILLO M, LÓPEZ-DÍAZ DE CERIO A, ZABALEGUI N, PÉREZ-CALVO J, PANIZO C, HERNANDEZ M, CUESTA B, ROCHA E, BENDANDI M. Feasibility of idiotype vaccination in relapsed B-cell malignancies. Haematologica. 2003 Dec;88(12):1438-40. ABSTRACT COURTESY OF PUBMEDLÓPEZ DÍAZ DE CERIO A, RODRÍGUEZ-CALVILLO M, INOGÉS SANCHO S, ZABALEGUI N, PANIZO C, PÉREZ-CALVO J, GARCÍA-FONCILLAS J, MERINO J, SÁNCHEZ-IBARROLA A, MARTÍN-ALGARRA S, ROCHA E, BENDANDI M. Estrategias terapéuticas con vacunas idiotípicas en el tratamiento del linfoma folicular. Hematol Citocinas Inmunoter Ter Cel. 2003;6(3);175-182. |
|
|